Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.10.18
Views: 700

Dr Vassiliki A. Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, USA

Dr Vassiliki A. Papadimitrakopoulou speaks with ecancer at the ESMO 2018 congress in Munich about an analysis of resistance mechanisms emerging in EGFR T790M advanced NSCLC patients treated with osimertinib.

Dr Papadimitrakopoulou outlines the genetic alterations detected in these patients, including a loss of T790 and a significant number showing MET amplification.

She also notes novel EGFR mutations and gene fusions, and considers alternative treatment schedules that may subvert these adaptations.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation